NCT00408590View on ClinicalTrials.gov

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 19, 2004

Primary Completion Date

August 31, 2012

Study Completion Date

November 7, 2017

Conditions
Ovarian CancerPrimary Peritoneal Cavity Cancer
Interventions
BIOLOGICAL

carcinoembryonic antigen-expressing measles virus

BIOLOGICAL

oncolytic measles virus encoding thyroidal sodium iodide symporter

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

laboratory biomarker analysis

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER